SCHEMBL95503

SCHEMBL95503

[CH2]c1ccc(C(=O)N2CCN(c3ccc(F)cc3)CC2)cc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.74
SMN1; SMN2 Q16637 4/20 0.71
MEN1 O00255 2/20 0.70
KMT2A Q03164 2/20 0.70
SLC6A7 Q99884 1/20 0.70
KDM4E B2RXH2 3/20 0.67
LMNA P02545 3/20 0.67
MAPK1 P28482 2/20 0.67
TSHR P16473 1/20 0.67
HTT P42858 1/20 0.67
ALDH1A1 P00352 2/20 0.63
HPGD P15428 1/20 0.63
USP2 O75604 1/20 0.61
NAMPT P43490 2/20 0.57
L3MBTL1 Q9Y468 1/20 0.57
CA12 O43570 1/20 0.56
CA1 P00915 1/20 0.56
CA2 P00918 1/20 0.56
CA9 Q16790 1/20 0.56
MAPT P10636 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10341777 0.92 HSP90AA1 (0.85) HSP90AA1SMN1; SMN2MEN1KMT2ASLC6A7
SCHEMBL3577850 0.86 HSP90AA1 (0.76) HSP90AA1SMN1; SMN2MEN1KMT2ASLC6A7
SCHEMBL21526333 0.85 HSP90AA1 (0.74) HSP90AA1SMN1; SMN2MEN1KMT2ASLC6A7
SCHEMBL94420 0.84 MEN1 (0.74) MEN1KMT2ASLC6A7LMNAMAPK1
SCHEMBL94700 0.84 MEN1 (0.60) HSP90AA1SMN1; SMN2MEN1KMT2ASLC6A7
SCHEMBL5908986 0.83 SMN1; SMN2 (1.00) HSP90AA1SMN1; SMN2MEN1KMT2ASLC6A7
SCHEMBL95296 0.82 SMN1; SMN2 (0.67) HSP90AA1SMN1; SMN2MEN1KMT2ASLC6A7
SCHEMBL6985975 0.82 CA12 (0.71) HSP90AA1SMN1; SMN2MEN1KMT2ASLC6A7
SCHEMBL22305103 0.82 CA12 (0.71) HSP90AA1SMN1; SMN2MEN1KMT2ASLC6A7
SCHEMBL94245 0.81 NAMPT (0.60) HSP90AA1SMN1; SMN2MEN1KMT2ASLC6A7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362252-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-01-29 US disclosed
EP-1797082-B1 CARBOSTYRIL COMPOUND OTSUKA PHARMA CO LTD (JP) 2012-08-29 EP disclosed
EP-2426128-A1 Carbostyril compound Otsuka Pharmaceutical Co., Limited (JP) 2012-03-07 EP disclosed
US-20100261705-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. 2010-10-14 US disclosed
US-7777038-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-08-17 US disclosed
US-20090326008-A1 NF-kappa B Inhibitor OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-12-31 US disclosed
CN-101489555-A Nf-kappa OTSUKA PHARMA CO LTD (JP) 2009-07-22 CN disclosed
EP-2043644-A1 NF- B INHIBITOR Otsuka Pharmaceutical Co., Ltd. (JP) 2009-04-08 EP disclosed
WO-2008010601-A1 NF- ϰB INHIBITOR OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2008-01-24 WO disclosed
US-20070179173-A1 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-02 US disclosed
EP-1797082-A1 CARBOSTYRIL COMPOUND Otsuka Pharmaceutical Company, Limited (JP) 2007-06-20 EP disclosed
WO-2006035954-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-04-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090326008-A1 NF-kappa B Inhibitor NFKBIA, NFKB2, IKBKB HSP90AA1 3237/4885SMN1; SMN2 3998/4885MEN1 4401/4885
US-20070179173-A1 Carbostyril compound GTF2F1, F3, GTF2F2 HSP90AA1 4109/4885SMN1; SMN2 3084/4885MEN1 3912/4885
US-20100261705-A1 CARBOSTYRIL COMPOUND GTF2F1, F3, GTF2F2 HSP90AA1 4109/4885SMN1; SMN2 3084/4885MEN1 3912/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.